137 related articles for article (PubMed ID: 9111578)
1. A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer.
Zimmermann S; Wels W; Froesch BA; Gerstmayer B; Stahel RA; Zangemeister-Wittke U
Cancer Immunol Immunother; 1997 Mar; 44(1):1-9. PubMed ID: 9111578
[TBL] [Abstract][Full Text] [Related]
2. Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer.
Zangemeister-Wittke U; Collinson AR; Frösch B; Waibel R; Schenker T; Stahel RA
Br J Cancer; 1994 Jan; 69(1):32-9. PubMed ID: 7506925
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
Hassan R; Viner JL; Wang QC; Margulies I; Kreitman RJ; Pastan I
J Immunother; 2000; 23(4):473-9. PubMed ID: 10916757
[TBL] [Abstract][Full Text] [Related]
4. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Friedman PN; Chace DF; Trail PA; Siegall CB
J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
[TBL] [Abstract][Full Text] [Related]
6. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer.
Myklebust AT; Godal A; Fodstad O
Cancer Res; 1994 Apr; 54(8):2146-50. PubMed ID: 8174121
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies.
Flatmark K; Guldvik IJ; Svensson H; Fleten KG; Flørenes VA; Reed W; Giercksky KE; Fodstad Ø; Andersson Y
Int J Cancer; 2013 Sep; 133(6):1497-506. PubMed ID: 23494569
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.
Batra JK; Jinno Y; Chaudhary VK; Kondo T; Willingham MC; FitzGerald DJ; Pastan I
Proc Natl Acad Sci U S A; 1989 Nov; 86(21):8545-9. PubMed ID: 2510169
[TBL] [Abstract][Full Text] [Related]
10. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
[TBL] [Abstract][Full Text] [Related]
11. Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats.
Engebraaten O; Sivam G; Juell S; Fodstad O
Int J Cancer; 2000 Dec; 88(6):970-6. PubMed ID: 11093823
[TBL] [Abstract][Full Text] [Related]
12. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
13. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin.
Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3358-62. PubMed ID: 2014255
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxin therapy for cancer.
Pai LH; Pastan I
JAMA; 1993 Jan; 269(1):78-81. PubMed ID: 8416411
[No Abstract] [Full Text] [Related]
17. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice.
Pearson JW; Sivam G; Manger R; Wiltrout RH; Morgan AC; Longo DL
Cancer Res; 1989 Sep; 49(18):4990-5. PubMed ID: 2504482
[TBL] [Abstract][Full Text] [Related]
18. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
Debinski W; Pastan I
Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Kreitman RJ; Hansen HJ; Jones AL; FitzGerald DJ; Goldenberg DM; Pastan I
Cancer Res; 1993 Feb; 53(4):819-25. PubMed ID: 8428363
[TBL] [Abstract][Full Text] [Related]
20. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
Pearson JW; Hedrick E; Fogler WE; Bull RL; Ferris DK; Riggs CW; Wiltrout RH; Sivam G; Morgan AC; Groves E
Cancer Res; 1990 Oct; 50(19):6379-88. PubMed ID: 2144790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
